NCT04958785
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with tumors that express programmed cell death ligand 1 (PD-L1); Patients with active untreated brain metastasis – see trial for details; Patients with prior treatment of CD47- or signal regulatory protein alpha-targeting agents
https://ClinicalTrials.gov/show/NCT04958785